FDA faces mounting pressure after delayed abortion pill safety review

The U.S. Food and Drug Administration is coming under renewed scrutiny after failing to release a long-promised safety review of mifepristone, the drug that begins the chemical abortion process and ends the life of a developing child in the earliest weeks of pregnancy. Key Takeaways: The FDA has delayed its promised safety review of the abortion pill, mifepristone. Pro-life medical experts and ...
Source